Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Heavily Pretreated Recurrent Ovarian Cancer (MITO32)
NCT04421547Phase 3Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2020
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole in ovarian cancer (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Proportion of patients alive at 12 months. Started Jun 2020; status: terminated.
02
Drugs
letrozole
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04421547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421547.